Asset Details
Do you wish to reserve the book?
Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis
Do you wish to request the book?
Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis
2012
Overview
Background
Interactions between Th1 and Th2 immune responses are of importance to the onset and development of allergic disorders. A Toll-like receptor 7 agonist such as AZD8848 may have potential as a treatment for allergic airway disease by skewing the immune system away from a Th2 profile.
Objective
To evaluate the efficacy and safety of intranasal AZD8848.
Methods
In a placebo-controlled
single ascending dose study
, AZD8848 (0.3-600 μg) was given intranasally to 48 healthy subjects and 12 patients with allergic rhinitis (NCT00688779). In a placebo-controlled
repeat challenge/treatment study
, AZD8848 (30 and 60 μg) was given once weekly for five weeks to 74 patients with allergic rhinitis out of season: starting 24 hours after the final dose, daily allergen challenges were given for seven days (NCT00770003). Safety, tolerability, pharmacokinetics, and biomarkers were monitored. During the allergen challenge series, nasal symptoms and lavage fluid levels of tryptase and α
2
-macroglobulin, reflecting mast cell activity and plasma exudation, were monitored.
Results
AZD8848 produced reversible blood lymphocyte reductions and dose-dependent flu-like symptoms: 30–100 μg produced consistent yet tolerable effects. Plasma interleukin-1 receptor antagonist was elevated after administration of AZD8848, reflecting interferon production secondary to TLR7 stimulation. At repeat challenge/treatment, AZD8848 reduced nasal symptoms recorded ten minutes after allergen challenge up to eight days after the final dose. Tryptase and α
2
-macroglobulin were also reduced by AZD8848.
Conclusions
Repeated intranasal stimulation of Toll-like receptor 7 by AZD8848 was safe and produced a sustained reduction in the responsiveness to allergen in allergic rhinitis.
Trial registration
NCT00688779 and NCT00770003 as indicated above.
Publisher
BioMed Central,BioMed Central Ltd,Nature Publishing Group,BMC
Subject
/ Adult
/ Allergens - administration & dosage
/ Allergy
/ Biological response modifiers
/ Female
/ Humans
/ Immunity
/ Ligands
/ Male
/ Medicine
/ Nose
/ Pneumology/Respiratory System
/ Respiratory Medicine and Allergy
/ Rhinitis
/ Rhinitis, Allergic, Perennial - prevention & control
/ Seasonal
/ Studies
/ TLR7
/ Toll-Like Receptor 7 - administration & dosage
